December 21, 2016—The 340B program mega-guidance was the chief concern of 340B Informed readers for the second year in a row.
In an exact repeat of 2015, four of this year’s 10 most-popular stories were about the guidance, including our top story of 2016. The mega-guidance’s status remains “pending review” at the White House Office of Management and Budget. But with President-elect Trump’s inauguration now just 30 days away, it is unlikely the guidance will be released.
- OMB Reports on Status of 340B Guidance and Regulations
- House Republicans Want to Know How EpiPen Scandal Affects 340B
- Four Big 340B Mega-Guidance Concerns for Hospitals
- President Seeks Express Rulemaking Power for 340B Program
- House Appropriators Concerned About 340B Guidance and Ceiling Price Website
- HRSA Seeing “Great Trends” in 340B Audits
- Final 340B Mega-Guidance Takes a Step Toward Release
- CMS Rule Likely Won’t Block Hospitals Using 340B in New Offsite Locations
- 340B Program Essential, Hospitals Say at Capitol Hill Briefing
- The 340B Drug Discount Program Explained
Register – 340B Coalition Winter Conference – February 1-3, 2017 – San Francisco, Calif.